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Background
BCL2 and Bax are two members of BCL2 family which is
responsible for the regulation of apotosis [1,2]. BCL2 pro-
tein duels with its counteracting twin, a partner known as
Bax (Figure 1). When Bax is in excess, cells execute a
death command. When BCL2 dominates, the program is
inhibited and cells survive. The intent is to propose a drug
complex which aids in regulation of the BCL2 and Bax
levels, aiding in treatment of autism. Navitoclax is known
drug responsible for inhibiting BCL2 production for the
treatment of cancer. We suggest a drug formulation of
navitoclax with a Bax channel locker.
Materials and methods
The structures of Navitoclax (Pubchem ID : 923564-51-6)
and Bax channel locker (Pubchem ID :335165-68-9) were
taken from Pubchem database. Their binding affinity and
energies with target components were analysed using
Autodock 4.0.The active site residues in the target proteins
BCL2 (Figure 2) and BAX were determined by literature
studies and using CastP and Sp align software. The admet
properties and pharmacological properties of the drug
were calculated using Discovery studio software.
Results
Based on the binding affinities of Navitoclax and Bax
Channel Locker with its respective target proteins BCL2
and Bax respectively, the target functional groups to con-
nect the two ligands were shortlisted. It was taken care the
responsible target binding sites aren’t affected with the
linkage. Four combinations (Figure 3) were created. Their
pharmacological properties were predicted insilico to
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Figure 1 (Left): Regulation of apoptosis pathway by family of BCL-2
proteins
Figure 2 (Top right): BCL-2 protein docked with Navitoclax [PDB
Id: 4LXE]
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shortlist the best combination. The predicted properties
inferred the drug complex to be non-carcinogenic, and
non-mutagen and may display moderate irritancy. The
novel drug complex can be further modified and analyzed
to get drug with lower molecular weight and displaying
low to no irritancy.
Conclusions
The admet and chemical properties suggest there are pos-
sibilities to consider the new drug complex designed for
further analysis.
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Figure 3 (Bottom right): Chemical structure of the novel designed drug complex
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